Adicet Bio, Inc. (ACET)

In our clinic reviewing the protocol design for lupus nephritis, the focus on prula-cel's Phase 1 update featuring 22 patients with a minimum of 6 months follow-up—including 13 patients with at least 12 months—is critical. We are closely monitoring the durability of CD20-targeting CAR gamma delta T cell therapies in autoimmune settings ahead of the anticipated 3Q/2026 topline results and potential pivotal trial start in 2H/2026.

As a biotech analyst evaluating ACET's market position, the consensus rating sitting at 'Moderate Buy' with an average 12-month price objective of $46.80 contrasts sharply with the current market cap of $85.18 million and share price around $9.11. The recent narrowing of the Q2 2026 net loss to $21.4 million due to lower RandD spending shows strict capital management, but upcoming regulatory catalysts in 3Q/2026 will dictate near-term sentiment.

On our trading desk, we noticed that Adicet reported an EPS of ($1.99) for Q2 2026, missing the consensus estimate of ($1.69) by $0.30. Despite the bottom-line miss, HC Wainwright recently revised its Q3 earnings estimates upward to ($2.05) per share from ($2.93). Liquidity looks robust with a current ratio of 7.66 and a minimal debt-to-equity ratio of 0.01, giving them sufficient runway for upcoming trials.

Looking at institutional coverage and brokerage revisions, we see divergent opinions ranging from sell/hold recommendations by individual firms up to strong buys, yielding an overall 'Moderate Buy' consensus from eight research entities. Guggenheim's previous reiteration with a $90.00 price target underscores the immense upside priced in by bulls, even as the stock trades near its 50-day moving average of $8.36.

From a translational research perspective, tracking the regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer targeted for 3Q/2026 is paramount. If cleared, enrollment is slated to begin in 4H/2026. This diversification into PSMA-targeted candidates alongside their in vivo CAR-T platform expansion broadens their clinical footprint beyond autoimmune conditions like SLE.